Pfizer: One of the world's premier biopharmaceutical companies
Starting with Charles Pfizer inventing an almond-flavored antiparasite medicine in 1849, our people have always been innovators and trailblazers, committed to finding the next cure. Learn More About Us Details
About - Pfizer
We’re in relentless pursuit of breakthroughs that change patients’ lives. We innovate every day to make the world a healthier place. It was Charles Pfizer’s vision at the beginning and it holds true today.
Careers | Pfizer
We’ve transformed growth and development at Pfizer to ensure that everyone can follow a path to their dream career, whether that’s climbing a traditional ladder or “zig-zagging” their way to a new role.
Pfizer-BioNTech COVID-19 Vaccine, Bivalent, and also includes information about the U.S. Food and Drug Administration (FDA)-licensed vaccine, COMIRNATY (COVID-19 Vaccine, mRNA) for use in individuals 12 years of age
Pfizer Provides Full-Year 2025 Guidance and Reaffirms Full-Year …
Dec 17, 2024 · Pfizer anticipates full-year 2025 revenues to be in the range of $61.0 to $64.0 billion, which includes the expectation of revenues from our COVID-19 products in 2025 being largely consistent with 2024 after excluding approximately $1.2 billion of non-recurring revenue for Paxlovid in 2024.
Celebrating 175 Years of Changing Lives at Pfizer
Jun 24, 2024 · Pfizer was founded with the dream to deliver medicines and vaccines that would have positive impacts on global health. Nearly two centuries later, Pfizer has been at the forefront of medical and pharmaceutical breakthroughs that have not only helped to change patient lives, but shaped history.
U.S. FDA Approves Pfizer’s BRAFTOVI® Combination Regimen as …
Dec 20, 2024 · BRAFTOVI in combination with cetuximab and mFOLFOX6 is the first and only combination regimen with targeted therapy approved for use as early as first-line for patients with metastatic colorectal cancer with a BRAF V600E mutation Accelerated approval is based on 61% overall response rate compared to 40% in control arm in the Phase 3 BREAKWATER ...
NUESTRO PROGRESO EN EL DESARROLLO DE UNA POTENCIAL …
El 18 de noviembre, Pfizer y BioNTech anunciaron que, después de realizar el análisis de eficacia final en su ensayo clínico de fase 3 en curso, la vacuna COVID-19 basada en ARNm cumplía con todos los criterios de valoración de eficacia primarios del estudio.
Pfizer and BioNTech Provide Update on mRNA-based …
Aug 16, 2024 · NEW YORK & MAINZ, Germany--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced top-line results from their Phase 3 clinical trial to evaluate the companies’ combined mRNA vaccine candidate against influenza and COVID-19 in healthy individuals 18-64 years of age. The ...
Purpose | Pfizer
Pfizer’s purpose is to deliver breakthroughs that change patients’ lives. R&D is at the heart of fulfilling Pfizer’s purpose as we work to translate advanced science and technologies into the therapies that matter most. Today, we are at a unique moment in biomedical innovation.